Details for Patent: 8,697,748
✉ Email this page to a colleague
Which drugs does patent 8,697,748 protect, and when does it expire?
Patent 8,697,748 protects DOJOLVI and is included in one NDA.
This patent has eight patent family members in four countries.
Summary for Patent: 8,697,748
| Title: | Glycogen or polysaccharide storage disease treatment method |
| Abstract: | A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases. |
| Inventor(s): | Roe; Charles R. (Rockwall, TX) |
| Assignee: | Baylor Research Institute (Dallas, TX) |
| Application Number: | 13/343,578 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Delivery; |
Drugs Protected by US Patent 8,697,748
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharm Inc | DOJOLVI | triheptanoin | LIQUID;ORAL | 213687-001 | Jun 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,697,748
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2573054 | ⤷ Sign Up | |||
| Canada | 2784420 | ⤷ Sign Up | |||
| Canada | 2784585 | ⤷ Sign Up | |||
| European Patent Office | 1773317 | ⤷ Sign Up | |||
| European Patent Office | 3300727 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
